Wortmannin

For research use only.

Catalog No.S2758 Synonyms: KY 12420

142 publications

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock
USD 747 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Wortmannin has been cited by 142 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XHblIvPSEQvF2= M{e4[FEuPCCm M1;WTWROW09? Mlfs[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> M3Oxc|I2PDlyM{iz
H1703 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvsdGNQOi53IN88US=> MYexMVQh\A>? MnS3SG1UVw>? MoPt[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MkS5NlU1QTB|OEO=
HUVECs MYrDfZRwfG:6aXPpeJkhSXO|YYm= MkPZNVAxKG6P M1nJWFI1KGh? MnrHZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NV7pUFBqOjV2NUCxPFY>
APRE-19 Ml7ORZBweHSxc3nzJGF{e2G7 MX21JO69VQ>? M2XOWFI1KGh? MkfMZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? MYiyOVMzQTZzNx?=
MDA-MB-231 M4jP[GFxd3C2b4Ppd{BCe3OjeR?= NUjnT4ppOcLizszNxsA> MVO0PEBp MYLEUXNQ NWrLb4Zt\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKHS{ZXH0[YQhf2m2aDCyOUDPxE1ib3[gSlEhd3JiRkKgxsA> MV:yOVMxODl|Mh?=
MCF7 MlHlSpVv[3Srb36gRZN{[Xl? M3HYT|ExOCCwTR?= Mn7INlQhcA>? NXzmOXBE\WyrbXnuZZRmeyCHMj3pcoR2[2WmIFHSSU1NfWNiYXP0bZZqfHl? NFPhN2IzPTF5MkW1Oy=>
HT-29  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrNeXoyNjYEoNM1US=> MmC2PVYhcA>? NGHTbYZl\WO{ZXHz[ZMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIlvcGmkaYTl[EBjgSCNWV7B NHvNeVYzPTBzMkGyNy=>
MO59K  MYfDfZRwfG:6aXPpeJkhSXO|YYm= MlrBOeKh|ryP MoewO{Bl MX;EUXNQ MlW1[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NF7XfnkzPDl3M{W2NS=>
MO59J M1PiVGN6fG:2b4jpZ4l1gSCDc4PhfS=> NEXTWXI2yqEQvF2= NXTkSGV4PyCm MUXEUXNQ Mmm4[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MoLXNlQ6PTN3NkG=
MO59K  M1HVUWFxd3C2b4Ppd{BCe3OjeR?= MXWxNEDPxE1? NVPkW5RIOjRiaB?= Ml64SG1UVw>? MoG3bY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv NW\WZY9nOjR7NUO1OlE>
MO59J NX\LTYdMSXCxcITvd4l{KEG|c3H5 MX[xNEDPxE1? MX2yOEBp NUfm[3gyTE2VTx?= MmDDbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv NGD4eGgzPDl3M{W2NS=>
HepG2 NYnZc5V5TnWwY4Tpc44hSXO|YYm= NGLKR2cyODBibl2= NYnFdXBuOC53IHi= MVrEUXNQ NXnLSVNp[myxY3vzJG1CNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NFjmSowzPDh4M{O1NC=>
A549  NGfHbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWzJOK2VcLi MV2yJIg> Ml3pd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? MXqyOFg1Pzh4Mx?=
A549  MYTGeY5kfGmxbjDBd5NigQ>? NXTuS45bOTEEoN88ceKh NVfNW4ZROTZiaB?= MnnpSG1UVw>? MXPtc4R2dGG2ZYOgeIhmKEmDVjDy[ZBtcWOjdHnvckBidmRiY3H1d4V{KHKndHXueIlwdiCxZjDOVEBqdiC2aHWgcpVkdGW3cz6= NGfkeVMzPDhyMkGxNS=>
SK-N-LO NXnzRnZ5TnWwY4Tpc44hSXO|YYm= MoHzNVAxKG6P NH\S[VYxNjViaB?= Mlju[IVkemWjc3XzJJRp\SC|dHnteYxidnRiZX\m[YN1eyCxZjDtc5JxcGmwZTDvckBCc3RicHjvd5Bpd3K7bHH0bY9v M{flN|I1PjV2NkC2
HL-60 M3WxTGZ2dmO2aX;uJGF{e2G7 M4fWUVAvOcLizszN Mn7aO|IhcA>? NGDROYRjdG:la4Og[IF{[XSrbnniMYlv\HWlZXSgZ4VtdCCmaX\m[ZJmdnSrYYTpc44> NV7FWYdkOjR4MEeyO|M>
HepG2  NInhXWNHfW6ldHnvckBCe3OjeR?= NWj6XWpDOjByIH7N NFHtVWsxNjViaB?= M37L[IF1fGWwdXH0[ZMhTm:6TzDwbI9{eGixconsZZRqd25? MYKyOFU{PTF7Mh?=
H520 NGi4N4xHfW6ldHnvckBCe3OjeR?= NGSyb2cyOMLizszN NXq2W5RROSCq MXLEUXNQ NEX0dlhl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> MUmyOFQ1Pzl|NR?=
H1975 MVzGeY5kfGmxbjDBd5NigQ>? NXnnUnE3OTEEoN88US=> NX3rRZB2OSCq NUS0No9TTE2VTx?= M13YTYRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> NUnC[FEzOjR2NEe5N|U>
MG-63 M2TwSWFxd3C2b4Ppd{BCe3OjeR?= NWHod491OTBiwsXN NXLGTG5KOTJiaB?= NX;Y[pE3\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? MYWyOFM2QDNyMR?=
5637 MYPBdI9xfG:|aYOgRZN{[Xl? M4fEVVExyqEQvF2= MWK0NEBucW5? MYDy[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> NEntTZozPDN|M{i2PC=>
HEK-293 MnvpSpVv[3Srb36gRZN{[Xl? MlrHNVUxdk1? NETYb3MyPiCq MlLFSG1UVw>? MkXB[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? MnHENlQ{OjR|Nk[=
SW480  MX7GeY5kfGmxbjDBd5NigQ>? NHXPV3oyPTCwTR?= NUHRZZpxOjBiaB?= MY\EUXNQ MoWxdoVlfWOnczDj[YxtfWyjcjDhZ4N2dXWuYYTpc44hd2ZizsKtZ4F1\W6rbh?= NXPrcWNDOjR|MkSzOlY>
HepG2 MknKSpVv[3Srb36gRZN{[Xl? NEjvSmEyODBibl2= MXSyOEBp M2XFW4F1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz MVKyOFI6PzVzMB?=
HCT 116  MUfGeY5kfGmxbjDBd5NigQ>? NVWwXohMOTByIH7N NEPkclAzPCCq NXPYcI9Z[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= MXeyOFI6PzVzMB?=
BEL/FU NYnCPZg1TnWwY4Tpc44hSXO|YYm= MnfjNUBuVQ>? MV[yOEBp NHjT[pdl\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? NFTGfZYzPDJ|MkC5PS=>
Huh7  MV;GeY5kfGmxbjDBd5NigQ>? MnHLN:Kh|ryP Mn3tNUBp NV3Gc28yemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? M1jQdlI1OTh2MUm2
A-375 NFzuUG5CeG:ydH;zbZMhSXO|YYm= M4n2PVQwQCEQvF2= MmrmNlQhcA>? MX3lcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li M3v3SFI1OTF|MUez
A-375-TS  M2TJRmFxd3C2b4Ppd{BCe3OjeR?= MkjROE85KM7:TR?= MlPRNlQhcA>? NHfEb4FmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NY\WepRXOjRzMUOxO|M>
Mel-HO M1OzZWFxd3C2b4Ppd{BCe3OjeR?= MnfYOE85KM7:TR?= MkTCNlQhcA>? MoHV[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NYfjXWNiOjRzMUOxO|M>
Mel-HO-TS Ml;oRZBweHSxc3nzJGF{e2G7 M4fMeFQwQCEQvF2= MYeyOEBp M3HpR4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NUn3[mJVOjRzMUOxO|M>
MeWo NVTlTm1USXCxcITvd4l{KEG|c3H5 NXvaRoE6PC96IN88US=> M3XxWVI1KGh? NW\Z[pYy\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NXzjcGxWOjRzMUOxO|M>
Mel-2a MmPtRZBweHSxc3nzJGF{e2G7 MVS0M|gh|ryP MmX6NlQhcA>? M{jUVIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NYjUZmo3OjRzMUOxO|M>
MDA-MB-231 MnfvSpVv[3Srb36gRZN{[Xl? M{WyclDjiJN2MECgcm0> M32zcFQhcA>? MkDPd5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWewOXF6OjJ7ME[yOVk>
MDA-MB-231 NHy4WJZHfW6ldHnvckBCe3OjeR?= MlLVOFAxKG6P M4PPclQhcA>? NGf3fmRl\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mkn6NlI6ODZ{NUm=
Jurkat NUmyT4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDISogxNjJ3LUGuNlUh|ryP Mn;uNlQwPDhiaB?= M3SzeGROW09? MkXEbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NULteHBtOTl5NUexPFU>
Namalwa MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHENE4zPS1zLkK1JO69VQ>? M1qwWFI1NzR6IHi= MmGzSG1UVw>? NUT2WVdJcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NIG2RmYyQTd3N{G4OS=>
Jurkat Mm\JRZBweHSxc3nzJGF{e2G7 NHXrOFcxNjJ3LUGuNlUh|ryP NE\CW2szPC92ODDo M2KyTmROW09? MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MoqyNVk4PTdzOEW=
Namalwa M336cGFxd3C2b4Ppd{BCe3OjeR?= MoLCNE4zPS1zLkK1JO69VQ>? M1jNWFI1NzR6IHi= NUPnfZN2TE2VTx?= NUDQN|ZscW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz Ml\uNVk4PTdzOEW=
K562 M3\SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW4bJMzPCCq MlPkTWM2OD1{NdMxNE4yPCCwTR?= NGPJRYkyQTZ4MkO2NS=>
SW1990 MnTvSpVv[3Srb36gRZN{[Xl? M4e2UVAvODFvMTFOwG0> NGnOd4UyKGh? MWLpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NHr4SYoyQTR4OUCyNC=>
RT112  Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;4NVDDqM7:TR?= M33aUFI1KGh? MYjEUXNQ MkDQ[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> NFfk[JQyQDd6N{izNi=>
MHG-U1 NH7r[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJRWgyOMLizszN NEDWRlgzPCCq NVTyc4UyTE2VTx?= NXnDO3Bk\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? M4TnVFE5Pzh5OEOy
SMMC-7721 NX7uWnRkSXCxcITvd4l{KEG|c3H5 NYD5OlNFOjBywrDuUS=> MkjFNlQhcA>? NEnXO3BqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| NFj0T4MyPzV3N{G5NS=>
SMMC-7721 M4jqZWZ2dmO2aX;uJGF{e2G7 NH;6d4UzODEEoH7N NG\nb|EzPCCq NWnicpRMfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= NYjQeHVvOTd3NUexPVE>
HeLa MWXGeY5kfGmxbjDBd5NigQ>? NWnMWHB4OTBywrDuUeKh MkDuNUBp M33PTIFtfGW{czD0bIUhdW:{cHjvcI9ogSCxZjD0bIUhfHKjboPm[ZJzcW5icnXjfYNtcW6pIHPvcZBienSvZX70 M3vKN|E3QDlyOUG1
MRC5VI M4fVXGZ2dmO2aX;uJGF{e2G7 NIjyfFgyOi53IH3N MXOwMlUhcA>? NF3Rc4xFVVOR MW\hZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NY\ySGlXOTZ{MkezPVQ>
AT5BIVA NUexVWN3TnWwY4Tpc44hSXO|YYm= NFjJcZAyOi53IH3N M4OzUVAvPSCq NVHSW2tGTE2VTx?= MUThZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NFzpS5YyPjJ{N{O5OC=>
M059J NFTlVmlHfW6ldHnvckBCe3OjeR?= M4XjfFEzNjVibV2= MlvrNE42KGh? M3jD[mROW09? NHq3Zmxi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MoKyNVYzOjd|OUS=
HeLa NVzCZVhNTnWwY4Tpc44hSXO|YYm= Mn[3NVIvPSCvTR?= MkK3NE42KGh? MX3EUXNQ M1XxbYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh MnjjNVYzOjd|OUS=
N2a NUjRZ2hkSXCxcITvd4l{KEG|c3H5 NXHvSI1nOC5zLUGwJO69VQ>? MmKwNkBp MnLqbY5lfWOnczDk[YNz\WG|ZXSgZ4VtdCC4aXHibYxqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M1vuVlE2QDR{N{[3
Jurkat  MkWwT4lv[XOnIFHzd4F6 NIrPdZJKSzVyIH;mJFI1KG6P NXzWbGFoOTV4NkS1NVk>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin|Wortmannin ic50|Wortmannin price|Wortmannin cost|Wortmannin solubility dmso|Wortmannin purchase|Wortmannin manufacturer|Wortmannin research buy|Wortmannin order|Wortmannin mouse|Wortmannin chemical structure|Wortmannin mw|Wortmannin molecular weight|Wortmannin datasheet|Wortmannin supplier|Wortmannin in vitro|Wortmannin cell line|Wortmannin concentration|Wortmannin nmr|Wortmannin in vivo|Wortmannin clinical trial|Wortmannin inhibitor|Wortmannin PI3K/Akt/mTOR inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID